# Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet

> **NCT03800381** · — · COMPLETED · sponsor: **University of Florida** · enrollment: 92 (actual)

## Conditions studied

- Tuberculosis
- Human Immunodeficiency Virus
- Coinfection

## Interventions

- **OTHER:** Observational PK study

## Key facts

- **NCT ID:** NCT03800381
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-28
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2024-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03800381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03800381, "Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03800381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*